|
GB201910389D0
|
|
Novel compounds, methods for their manufacture, and uses thereof
|
|
US2019270563A1
|
|
Pharmaceutical formulation
|
|
US2018042842A1
|
|
Pharmaceutical formulations
|
|
GB201517215D0
|
|
Use of cannabinoids in the treatment of inflammatory skin diseases
|
|
GB201515986D0
|
|
Use of cannabidiol in the treatment of mental disorders
|
|
GB201514079D0
|
|
Use of cannabinoids in the treatment of epilepsy
|
|
GB201418166D0
|
|
Use of cannabidiol in the treatment of intractable epilepsy
|
|
GB201418172D0
|
|
Use of cannabidiols in the treatment of degenerative skeletal muscle diseases
|
|
GB201418171D0
|
|
Use of cannabinoids in the treatment of epilepsy
|
|
GB201418169D0
|
|
Use of cannabidiol in the treatment of intractable epilepsy
|
|
GB201418170D0
|
|
Use of cannabidiol in the treatment of intractable epilepsy
|
|
GB201411496D0
|
|
Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
|
|
GB201411467D0
|
|
7-hydroxy cannabidiol (7-OH-CBD) for use in the treatment of non-alcoholic fatty liver disease (NAFLD)
|
|
GB201410771D0
|
|
Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
|
|
US2016243075A2
|
|
Tetrahydrocannabivarin (thc) for use in the protection of pancreatic islet cells
|
|
GB201310910D0
|
|
The use of phytocannabinoids in the treatment of ovarian carcinoma
|
|
GB201210142D0
|
|
Synergistic therapies for neuroprotection
|
|
GB201120067D0
|
|
Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
|
|
GB201120066D0
|
|
Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
|
|
GB201115711D0
|
|
Phytocannabinoids for use in the treatment of invasive cancers or metastases
|
